| name | es-scheduled-insulin-preferred |
| description | In most adult patients with hyperglycemia (with or without known type 2 diabetes) hospitalized for noncritical illness, scheduled insulin therapy is preferred over noninsulin agents for glycemic management. Clinicians should consider this when they ask, "Patient has hyperglycemia, should we start insulin or try a noninsulin drug?" |
Prefer scheduled insulin therapy over noninsulin therapies for most hospitalized hyperglycemia patients
STEP 1 — Gather Information
Collect: admission diagnosis (noncritical illness), point‑of‑care glucose (>140 mg/dL defines hyperglycemia), diabetes history, home medications, renal function (eGFR), NPO status, risk factors for hypoglycemia (age >65, low BMI, CKD, prior hypoglycemia), and current insulin use.
Action: Proceed to assess eligibility for scheduled vs noninsulin therapy.
STEP 2 — Rule In / Rule Out
Is the patient hospitalized for a noncritical illness and hyperglycemic (BG >140 mg/dL)?
- Yes: Continue to classification.
- No: Consider alternative glycemic strategies or routine care.
Decision: If criteria met, move to step 3; otherwise, follow local protocols for normoglycemia or critical illness.
STEP 3 — Classify or Stratify
Does the patient have mild hyperglycemia (BG <180 mg/dL), be clinically stable, and be near discharge (expected ≤24 h) with known type 2 diabetes?
- Yes: Consider a noninsulin agent (e.g., DPP4i with correction insulin) per Recommendation 7.2.
- No: Proceed to scheduled insulin therapy.
Decision: If mild/stable/near‑discharge, evaluate noninsulin option; otherwise, schedule insulin.
STEP 4 — Decide
Initiate scheduled insulin therapy (basal‑bolus or basal plus correctional insulin) targeting glucose 100‑180 mg/dL, with point‑of‑care checks before meals and at bedtime. Adjust doses based on glucose trends and clinical status.
Action: Start scheduled insulin and monitor for hypoglycemia.
Clinical Guardrails / Mimics / Pitfalls
- Do not rely on sliding‑scale insulin alone as the sole regimen.
- Avoid metformin in eGFR <30 mL/min/1.73 m² or acute kidney injury.
- Avoid sulfonylureas due to high hypoglycemia risk in hospitalized patients.
- Avoid SGLT2 inhibitors in volume‑depleted, NPO, or hypotensive patients.
- Do not use noninsulin agents in patients with type 1 diabetes, significant hyperglycemia (>250 mg/dL), or high hypoglycemia risk.
- Never delay insulin initiation while awaiting noninsulin agent effect.
Concrete Clinical Example
A 68‑year‑old woman admitted for community‑acquired pneumonia has a random glucose of 168 mg/dL, known type 2 diabetes on metformin at home, baseline creatinine 0.9 mg/dL, and is eating regular meals. She is not near discharge. According to the algorithm, she proceeds to step 4 and receives basal‑bolus insulin (glargine 10 U nightly plus aspart 4 U TID before meals) with correctional insulin as needed.
Source: Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2022, https://doi.org/10.1210/clinem/dgac278
